Worsening of heart failure by coronavirus disease 2019 is associated with high mortality

Autor: Francisco Akira Malta Cardoso, Ranna Santos Pessoa, Silvia Moreira Ayub Ferreira, Bruno Biselli, Mariana Vieira de Oliveira Bello, Vera Maria Cury Salemi, Ludhmila Abrahão Hajjar, Ivna Girard Cunha Vieira Lima, Brenno Rizerio Gomes, Edimar Alcides Bocchi, Paulo Roberto Chizzola, Robinson Tadeu Munhoz
Rok vydání: 2021
Předmět:
Adult
Male
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty
Critical Care
medicine.medical_treatment
030204 cardiovascular system & hematology
SARS‐CoV‐2
law.invention
03 medical and health sciences
0302 clinical medicine
COVID‐19
law
Original Research Articles
Internal medicine
medicine
Humans
Original Research Article
030212 general & internal medicine
Aged
Retrospective Studies
Heart Failure
Heart transplantation
Ejection fraction
business.industry
Cardiogenic shock
COVID-19
Cardiovascular Agents
Stroke Volume
Decompensated heart failure
Middle Aged
medicine.disease
Intensive care unit
Hospitalization
Survival Rate
Treatment Outcome
lcsh:RC666-701
Shock (circulatory)
Heart failure
Cardiovascular agent
Cardiology
Heart Transplantation
Female
Dobutamine
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Inotropic drugs
medicine.drug
Zdroj: ESC Heart Failure
ESC Heart Failure, Vol 8, Iss 2, Pp 943-952 (2021)
ISSN: 2055-5822
Popis: Aims Patients with advanced heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) and concurrent coronavirus disease 2019 (COVID‐19) might have a higher risk of severe events. Methods and results We retrospectively studied 16 patients with advanced HFrEF who developed COVID‐19 between 1 March and 29 May 2020. Follow‐up lasted until 30 September. Ten patients previously hospitalized with decompensated HFrEF were infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during hospitalization. Six patients undergoing ambulatory care at initiation of COVID‐19 symptoms were hospitalized because of advanced HFrEF. All patients who experienced worsening of HFrEF due to COVID‐19 required higher doses or introduction of additional inotropic drugs or intra‐aortic balloon pump in the intensive care unit. The mean intravenous dobutamine dose before SARS‐CoV‐2 infection in previously hospitalized patients (n = 10) and the median (inter‐quartile range) peak intravenous dobutamine dose during SARS‐CoV‐2 infection in all patients (n = 16) were 2 (0–7) μg/kg/min and 20 (14–20) (P
Databáze: OpenAIRE
Externí odkaz: